Recently,Medtronic CEOGeoff Martha At the J.P. Morgan Healthcare Conference, it was stated thatThe company will take the initiative to make strategic acquisitions, focusing on high-growth and near-commercialization targets for strengthening acquisitions.It is reported that, as Medtronic seeks to expand its business portfolio,2026This year, the company will increase its efforts to make acquisitions.

Martha Revealed in the conference speechMedtronic's M&A strategy will precisely target "high-growth, near-commercialization" niche areas, with bolt-on acquisitions as the core approach.This M&A model will focus on small and medium-sized targets that are highly synergistic with the company's existing business.Aimed at quickly filling the gap in the product pipeline and strengthening technical advantages, with pulsed field ablation technology, renal denervation, Tibial Nerve Modulation for Urgency Urinary Incontinence and the Four "Generational Growth Drivers" of Surgical Robots Are Complementary.

"We are taking the initiative through strategic mergers and acquisitions, rather than passively waiting for internal growth to take effect."Martha It was emphasized that reinforcing mergers and acquisitions will become an important supplement to the company's growth, helping it continuously expand its competitive advantage in core sectors. This strategic direction has also become the most focused topic among investors at this conference.

In fact, Medtronic's increased focus on mergers and acquisitions is not a sudden decision.2025Year8Month, well-known investment institutionsElliot Increasing the stake in Medtronic to become its major shareholder, one of the two core initiatives reached by both parties at that time was "strengthening M&A layout."

To advance this strategy, Medtronic has established two special committees, among which the "Growth Committee" will be directly responsible for the evaluation and execution of value-added bolt-on acquisitions, internal R&D investment, and potential asset divestitures, including the ongoing plan to spin off its diabetes business into a separate publicly listed company.

CFO of MedtronicThierry PiétonThe establishment of the two major committees is highly aligned with the company's strategic goals and daily operational model."One focuses on growth, the other specializes in improving profit margins, achieving direct synergy between internal operations and board decision-making."He emphasized that this mechanism optimization will significantly accelerate decision-making speed, providing strong support for the implementation of M&A strategies, "a very wise move."

Regarding the issue of capital security that investors are concerned about,PiétonGave a clear response:"The company's balance sheet is strong, with sufficient capital reserves to support a significant number of M&A transactions."According to reports,2025In the fiscal year, Medtronic achieved336Billion dollars in revenue, and owns52Billion USD in free cash flow.

In conjunction with Medtronic's corporate scale,MarthaThe transaction scale of reinforcing M&A has been clearly defined, mainly focusing on the "hundreds of millions to billions of dollars range."This range is distinct from2015The mega-deal of acquiring Covidien in the year is also higher than the early scattered technology acquisitions, allowing Medtronic to maintain decision-making flexibility while ensuring that the target has sufficient technological barriers.

On the basis of clarifying the M&A principles,Martha Directly Pointing2026The core goal of the year is to focus resources on two major areas: the iterative improvement of cardiac ablation technology and the ecological construction of surgical robots.This choice precisely targets two high-growth tracks in the medical device industry, combined corresponding to over300Billion-dollar market space.

Screenshot source: Medtronic official website

Cardiac Ablation

According to the financial report,2025Medtronic Cardiovascular Business Achievements in the Fiscal Year125Billion USD in revenue, year-over-year growth6.3%. And pulsed field ablation (PFA) is a technological revolution in the cardiovascular field, corresponding to ultra130Billion-dollar market, with annual growth exceeding25%。

Screenshot source: Medtronic official website

2025Year11In the month, Medtronic announced2026Fiscal YearQ2's performance, the company's total revenue this quarter89.6Billion USD, year-on-year growth6.6%. Among them,The significant contribution of the cardiac ablation business has accelerated Medtronic's growth rate, which is mainly due toAfferaSphere-9AndPulseSelectPFAStrong Commercial Demand for Catheters Drives Revenue Growth in Cardiac Ablation Solutions Business71%, Growth in the United States128%。

Among them,PFAGrowth in the U.S. and overseas markets both exceeded300%；It is expected that the growth will continue to accelerate in the third quarter, and2026The fiscal year has seen continuous market share growth, and it is expected to2025Achieved at the beginning of the fiscal year10Incremental revenue of US$ billion.

Obviously, Medtronic's acquisition strategy is highly targeted. On the one hand, it aims atPFA The direction of technology upgrade, especially integrationAI The multimodal ablation system with real-time ECG analysis module is becoming a new industry benchmark due to its low surgical recurrence rate. Currently, Medtronic'sPulseSelect The system has achieved economies of scale but still has shortcomings in the 3D mapping field, while Boston Scientific addresses this through acquisitions.Cortex ObtainOptiMap™ system, "Mapping" has been achieved+ The closed-loop advantage of "ablation" is precisely the area where Medtronic urgently needs improvement.

Surgical Robot

Surgical robots, as the fundamental equipment for the future of surgery, have currently broken through200billion US dollars, with an annual growth rate of25%, among which the penetration rate of robots in the orthopedic and cardiovascular fields is transitioning from15%Fast Track30%Step forward.

Screenshot source: Medtronic official website

Medtronic's M&A strategy in the surgical robotics field focuses on technology completion, aiming to enhance itsHugo The Ecological Layout of the Robotic Platform.

It was revealed that Medtronic will focus on three types of targets: first,With autonomous navigation functionAI Algorithm Enterprises,Can improve surgical accuracy to0.1 Millimeters; Second,Manufacturer of dedicated consumables for adaptive robots,Such as Zimmer Biomet's acquisition ofMonogram Such3D Printed implants company; ThirdlySpecialized Robot Companies in Niche Fields, especially in the mature technologies of neurosurgery and joint replacement.

This layout is backed by profound industry insights. The current competition in surgical robotics has evolved from a contest of single devices to an ecosystem battle: Johnson & Johnson integratesVELYS Orthopedic Robot andOTTAVA Soft Tissue System, Stryker throughMako Building an Orthopedic Closed Loop, B. Braun AcquiresTDS Enhance Microsurgery Capabilities.

Medtronic completes the ecological chain of robotic devices, consumables, and algorithms through mergers and acquisitions.It is precisely to avoid repeating the覆辙of early single-device competition,What is needed is not isolated technology, but solutions that can be integrated into existing platforms.

Review of Medtronic's Recent20The history of acquisitions over the years has seen three major strategic transitions, profoundly reflecting the developmental logic of the medical device industry.

2005-2010Year,Medtronic Builds Absolute Barrier in Cardiovascular Field with "Technology Complement" as the Core.

2007Year of AcquisitionCoreValveAchieving Success in Transcatheter Aortic Valve Technology,2009Included in the yearVentorStrengthening Interventional Valve Business, Laying the FoundationTAVRPioneer Position in the Track (The Current Scale of This Track Exceeds120Billion USD); Acquired in the same periodAblation FrontiersAndArdian, perfecting the full-chain layout of cardiovascular interventions.2007Year39Billion-dollar acquisitionKyphon, entering the spinal market and integrating with the previously acquiredSofamor DanekForming synergies to pave the way for becoming the global leader in this field. This phase of mergers and acquisitions focuses on the core, making the cardiovascular business account for more than30%，2010Profit per capita in the fiscal year reached10Million USD of the industry's top level.

2011-2015Year,2015Year430The acquisition of Covidien for billions of dollars became a turning point. This largest transaction in the industry allowed Medtronic's revenue to increase from170Soared to $ billion290billion dollars, surpassing Johnson & Johnson to top the global market, expanding the workforce to910,000 people.

But behind the scale expansion, operational efficiency has plummeted: per capita revenue has dropped to33Million US dollars, per capita profit halved, and then the profit stagnated for eight years at50About X billion US dollars. The diversified businesses brought by Covidien have led to an bloated matrix, internal organizational friction, and a dilution of R&D focus, causing it to lag behind in subsequent technological iterations. This confirms the industry rule that "the dividends of scale are not as enduring as the dividends of technology."

2016-2024Year,The Pain of Covidien's Acquisition Drives Strategic Transformation.2016After the year, focus on robots and digital technology,2018Year of AcquisitionMazor RoboticsEntering the surgical robot track,2020Included in the yearAISurgical guidance companies are transitioning to become "solution providers."2021Further contraction to a "small and precise" targeted reinforcement after the year.2022Year of AcquisitionAfferaStrengthening Cardiac Electrophysiology Technology,2024Included in the yearFortimedix SurgicalPerfect the consumables ecosystem for robots.

And inElliotAfter becoming the largest shareholder, Medtronic's transformation accelerated, divesting low-profit, non-core businesses such as diabetes, and reducing the asset-liability ratio.38%。This strategy resonates with competitors and also serves as a true reflection of the idea that "the value of mergers and acquisitions lies not in scale, but in the defensive and synergistic nature of technology."

——

Martha The speech at the J.P. Morgan Conference marked a clear conclusion to Medtronic's merger and acquisition strategy: from500From Massive Expansion to Precise Targeting: This Giant Has Finally Found the Balance Between Scale and Innovation. Its Dual-Focus Strategy on Cardiac Ablation and Surgical Robotics Aligns with Global Medtech Trends and Answers the Industry’s Ultimate Pursuit of "Technology Reigns Supreme."

For the medical device industry, Medtronic's transformation is a significant bellwether.2024 Global Medical Device M&A Transaction Volume Reached in [Year]1280 billion dollars, of which reinforcing M&A accounted for more than 70% for the first time, and giants such as Stryker and Boston Scientific have followed this strategy.

Looking back, the summary of Medtronic's two-decade mergers and acquisitions history also serves as a forecast for the industry’s future. Some believe that with the evolution of cardiac ablation technology and the growing adoption of surgical robots, Medtronic's precise M&A strategy will continue to be tested by the market. In response, DeviceChina will keep following and reporting on the developments.